Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STARS: Gaboxadol in Angelman Syndrome
NCT02996305Phase 2Completed
- Sponsor
- Healx
- Start
- Jan 2016
- Primary completion
- Jun 2018
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial of gaboxadol in Angelman syndrome (AS) (3 arms), sponsored by Healx. Primary endpoint: Incidence of Adverse Events at 12 weeks. Started Jan 2016; status: completed.
02
Drugs
gaboxadol
03
Conditions
Angelman syndrome (AS)
Beyond the preview
Go deeper on NCT02996305.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02996305.